Explore Functional Potency Assays for Cancer Immunotherapy Research
Download the Cancer Immunotherapy Handbook to discover new quantitative methods to monitor immune cell behavior in vitro.
In addition to being robust and simple, the ideal in vitro assay should also be highly predictive of how the therapy will behave in animal models, and ultimately, in human patients. To gain a more complete and nuanced view of cancer cell killing, the xCELLigence® Real Time Cell Analysis (RTCA) assay captures dynamic cell behavior that is missed by more labor intensive endpoint methods.
Applications in the Cancer Immunotherapy Handbook include:
- Genetically Engineered T Cell-Mediated Cell Killing (CAR-T)
- Checkpoint Inhibitors
- Antibody-Dependent Cell-Mediated Cytolysis (ADCC)
- Bispecific T Cell Engagers (BiTEs) and Bispecific Antibodies
- Oncolytic Viruses
- Liquid Tumor Killing
Read the Latest Publication
Scientists at H. Lee Moffitt Cancer Center publish in JCI Insight “4-1BB enhancement of CAR T function requires NF-κB and TRAFs”
Target cell killing is monitored by xCELLigence Real Time Cell Analysis.
Figure 7D shows Cytotoxicity of h19BBz CAR T cells with TRAF overexpression.
Figure 7E shows Cytotoxicity of human CD33–targeted CAR (h33BBz) T cells with different scFvs.
Why Should You Analyze Cell Behavior in Real time?
- Automated Real Time Measurements for hours or days
- Highly Sensitive and Label-Free
- Increased Throughput
- Convenient Data Analysis (easily calculate % cytolysis and KT50)